title: "Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.
abstract: HER2-targeted therapy has moved beyond trastuzumab to include other monoclonals targeting the cell surface, receptor tyrosine kinase inhibitors of HER2, and antibody-drug conjugates. Afatinib, a small molecule receptor tyrosine kinase inhibitor, now joins the ranks of HER2-targeting agents in combination with trastuzumab. The combination brings new opportunities and challenges.
authors.affiliation: Stanford University School of Medicine, Stanford, California. gsledge@stanford.edu.
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
authors.affiliation: Stanford University School of Medicine, Stanford, California.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Pegram
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases